包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
EIDD-2801 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。EIDD-2801 显示出广泛的抗流感病毒 (influenza virus) 和冠状病毒 (coronaviruses) 的活性,如?SARS-CoV-2,MERS-CoV,SARS-CoV。EIDD-2801 有用于 COVID-19 和季节性,流行性流感的潜力。
Animal Model: | C57BL/6 mice (intranasal infection with SARS-CoV)[1] |
Dosage: | 50, 150, 500 mg/kg |
Administration: | Oral; every 12 hours for 3 days |
Result: | Body weight loss is significantly diminished or prevented. |
产品描述 | EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment. Reference: |